Copernicus Therapeutics Inc.

Nucleic Acid Nanoparticles for Treating Human Diseases

CopernicusLogo1Cutout3.jpgTubes.jpg4413SM2.jpg

OTHER

Other Applications of Copernicus’ Technology (Lung, Brain, Eye, Cancer)


As a platform technology enabling the delivery of nucleic acid therapeutics, Copernicus can choose from many potential disease indications that could benefit from our technology.  The CF, RP, and PD programs provide guidance for treating other diseases of the lung, eye, and brain.  Once one program is developed for each of these three main tissues, the time, expense and risk is accordingly markedly reduced for developing other disease therapeutics.  Preliminary data in preclinical cancer models are encouraging, and nucleolin targeting may be involved in cancer cell uptake and NP trafficking to the nucleus.  To show the extent of our platform technology, some examples (not designed to be an all-inclusive list) of these potential future disease targets are listed below.


Other Lung Indications


•    Asthma (severe)
•    Chronic Obstructive Pulmonary Disease (COPD)
•    Lung Infections (influenza, SARS, etc.)
•    Pulmonary Fibrosis


Other Brain Disorders


•    Alzheimer’s disease
•    Multiple Sclerosis
•    Traumatic Brain Injury
•    Epilepsy
•    Stroke


Other Eye Diseases


•    Retinitis Pigmentosa (there are multiple genetic forms of RP)
•    Macular Degeneration (wet and/or dry form)
•    Diabetic Retinopathy
•    Glaucoma


Cancer


•    many cancers may be amenable to treatment with DNA nanoparticles
•    cell surface nucleolin is expressed by many tumors and the tumor neovasculature